Experimental pill helped with weight loss in Eli Lilly trial
The medicine, called orforglipron, belongs to a class of blockbuster weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a hormone that makes people feel full for longer.
Most GLP-1 drugs – like Ozempic, Wegovy, and Mounjaro – must be injected, so pharmaceutical companies have been racing to find alternatives.
Lilly's pill may be the first to get there. The company plans to ask regulators to approve orforglipron by the end of the year, and said it is ready to begin rolling out the medicine globally.
If it's approved, the pill could offer 'a convenient alternative to injectable treatments,' Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a statement.
The clinical trial included more than 3,100 adults who were overweight or obese and had a weight-related health problem other than patients with diabetes.
After 72 weeks, the participants taking 36mg of orforglipron per day lost an average of 12.4 kilograms, or 12.4 per cent of their body weight.
Notably, that is not as much as people on other anti-obesity medicines. In one study, for example, people taking Novo Nordisk's Wegovy lost 13.2 per cent of their weight and those on Lilly's Zepbound lost 20.2 per cent over 72 weeks.
But the ability to take orforglipron as a daily pill rather than an injectable jab may drive up demand.
In the study, other cardiovascular risk factors also improved for patients, including their cholesterol, triglycerides, and blood pressure.
Orforglipron's side effects were mostly gastrointestinal, for example, constipation, diarrhoea, and vomiting, similar to other weight loss drugs.
Simon Cork, a senior lecturer in physiology at Anglia Ruskin University in the United Kingdom, said the findings are a 'positive step forward in the development of these class of drugs'.
Eli Lilly reported the data in a news release, and it has not yet been published in a peer-reviewed journal. The company said it will release more details next month at the European Association for the Study of Diabetes (EASD).
"Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," Custer said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
LeMonde
2 days ago
- LeMonde
Trump keeps up the pressure on pharmaceutical companies amid tariff uncertainty
In recent months, pressure on pharmaceutical manufacturers has continued to mount across the Atlantic due to tariff uncertainty, demands for lower drug prices and disruptions caused by shifting policies or staff changes within US health agencies. Although laboratories remain exempt from tariffs for now, they have tried to present a relatively calm front. Still, Donald Trump's repeated attacks on the industry do little to ease concerns. The US president once again caused a stir on August 5. Speaking on CNBC, Trump reiterated his threat to raise tariffs on health products imported into the US to dramatic levels, aiming to force drug manufacturers to bring their production back onto American soil. "We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years maximum, it's going to go to 150%, then it's going to go to 250%, because we want pharmaceuticals made in our country," he stated. Manufacturers − under pressure for months from the US administration to comply with Trump's demands − have already announced a series of major investments in the US since February. American laboratories such as Eli Lilly, Johnson & Johnson, AbbVie, Bristol Myers Squibb, Gilead and Regeneron; Swiss companies Roche and Novartis; Japan's Takeda; France's Sanofi; and the United Kingdom's AstraZeneca have together pledged nearly $320 billion over the next five years to strengthen and expand their industrial presence in the US.
Euronews
5 days ago
- Euronews
Portugal limits weight loss drug prescriptions to prevent misuse
Portugal is restricting doctors' ability to prescribe blockbuster weight loss drugs and monitors that track blood sugar levels, over concerns that they are being misused. As of Friday, only doctors from four medical specialties will be able to prescribe glucose sensors and drugs like Ozempic, Wegovy, and Mounjaro, which are known as glucagon-like peptide-1 (GLP-1) receptor agonists. Used to treat type 2 diabetes and obesity, the medicines help people lose weight by mimicking a hormone that makes them feel full for longer. The injectable drugs are in high demand, though, which has led to availability problems on the market. This is the case with Ozempic from the Danish laboratory Novo Nordisk. Ozempic is only approved in Portugal to treat type 2 diabetes, but it is highly sought after for weight loss. Mounjaro (Eli Lilly) and Wegovy (Novo Nordisk) are approved for both diabetes and obesity. In the first four months of 2025, Portuguese consumers spent around €21 million on these medicines. Now, only doctors from the approved specialties – endocrinology and nutrition, internal medicine, paediatrics, and general and family medicine – will be able to prescribe them. Glucose sensors have also been in high demand by non-diabetics, causing a shortage of these monitors in pharmacies. According to the Público newspaper, they are prescribed by doctors who do not work with diabetes patients, and are highly sought after by dieters, athletes, influencers, and even for use on animals. Portugal's Ministry of Health posted the regulation in April, warning of "recent reports of improper access to and use of these same technologies, which have jeopardised their availability to those who actually need them". "This decree aims to regulate and correct these distortions, promoting effective and adequate access to these essential health tools," the ministry said. The president of the Portuguese Society of Diabetology (SPD) praised the measure, but says it is late and may not solve the problem of difficult access to these medicines. "We're waiting to see if [the measure] will simplify or facilitate access," said João Raposo, speaking to the Lusa news agency. "I personally have some doubts, because I have the idea that the number of prescriptions outside of these specialties is not significant," Raposo added. He said that diabetics and doctors are not opposed to these drugs being used to treat obesity. But there are "anomalous prescriptions and a lack of monitoring of these people," he said. "Health cannot be subject to the laws of the market, because we know that it is very tempting for this population, which is desperately looking for solutions. The market has worked and we shouldn't have let it happen," he added. GLP-1 agonist medicines are reimbursed by the Portuguese state at 90 per cent. Sensor reimbursement can be as high as 85 per cent. In addition to prescriptions, there is also a high demand for these medicines on the black market, which can lead to problems with counterfeiting.
Euronews
6 days ago
- Euronews
Experimental pill helped with weight loss in Eli Lilly trial
An experimental once-daily pill to treat obesity can help people lose a significant amount of weight, according to new data from drugmaker Eli Lilly. The medicine, called orforglipron, belongs to a class of blockbuster weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which work by mimicking a hormone that makes people feel full for longer. Most GLP-1 drugs – like Ozempic, Wegovy, and Mounjaro – must be injected, so pharmaceutical companies have been racing to find alternatives. Lilly's pill may be the first to get there. The company plans to ask regulators to approve orforglipron by the end of the year, and said it is ready to begin rolling out the medicine globally. If it's approved, the pill could offer 'a convenient alternative to injectable treatments,' Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a statement. The clinical trial included more than 3,100 adults who were overweight or obese and had a weight-related health problem other than patients with diabetes. After 72 weeks, the participants taking 36mg of orforglipron per day lost an average of 12.4 kilograms, or 12.4 per cent of their body weight. Notably, that is not as much as people on other anti-obesity medicines. In one study, for example, people taking Novo Nordisk's Wegovy lost 13.2 per cent of their weight and those on Lilly's Zepbound lost 20.2 per cent over 72 weeks. But the ability to take orforglipron as a daily pill rather than an injectable jab may drive up demand. In the study, other cardiovascular risk factors also improved for patients, including their cholesterol, triglycerides, and blood pressure. Orforglipron's side effects were mostly gastrointestinal, for example, constipation, diarrhoea, and vomiting, similar to other weight loss drugs. Simon Cork, a senior lecturer in physiology at Anglia Ruskin University in the United Kingdom, said the findings are a 'positive step forward in the development of these class of drugs'. Eli Lilly reported the data in a news release, and it has not yet been published in a peer-reviewed journal. The company said it will release more details next month at the European Association for the Study of Diabetes (EASD). "Obesity is one of the most pressing global health challenges of our time, driving global chronic disease burden and impacting more than one billion people worldwide," Custer said.
